A Machine-Learning Drug Design Platform Company BUSINESS OVERVIEW
|
|
- Clarissa French
- 5 years ago
- Views:
Transcription
1 A Machine-Learning Drug Design Platform Company BUSINESS OVERVIEW
2 Introduction Revolutionizing Drug Discovery and Design Through Artificial Intelligence The $1 trillion global pharmaceutical industry faces a growing crisis Traditional methods for developing new drugs are no longer financially viable New, faster, cheaper methods are essential for Big Pharma to sustain profitability Artificial intelligence (AI) and Machine Learning (ML) based approaches can replace brute force experimentation and needle in a haystack luck with precise and vastly more efficient drug engineering solutions Only one company Spektron Systems works closely with the FDA to establish reliable, repeatable methods for cost-effective new AI/ML drug discovery 1
3 Drug Discovery is No Longer Viable in Big Pharma The Problem Industry-wide Internal Rates of Return Are Rapidly Heading Toward 0% Average cost of introducing a new drug has reached $2.6 billion* Pre-clinical trial cost alone is $1+ billion Glacially slow R&D: years per drug The low-hanging fruit has been plucked Investment returns are low and dropping Financiers, not scientists, now drive most R&D decisions; too often they back the wrong picks Huge, critical patient needs going unmet *Total capitalized costs per new drug approval (in 2013 dollars) according to Journal of Health Economics, May 2016
4 The Solution Spektron has leveraged decades of FDA tech investments* and knowledge to create a new drug discovery platform: Q-MAP Q-MAP applies proprietary AI/ML tools to replace costly trial-and-error R&D with precise drug molecule engineering With Q-MAP, Spektron can: Reduce new drug discovery cycle from years to 3.5 years or less Slash new drug discovery investment from over $1 billion to approximately $10 million Q-MAP is a game changer for new drug discovery and design *Approx. $20M in FDA funding has built technologies licensed by Spektron Wet Lab Experimentation AI Molecule Engineering 3
5 The Company Operating in Little Rock, Arkansas, Spektron s foundational technology emerged from the nearby National Center for Toxicological Research (NCTR), a world-renowned FDA facility Decades of NCTR research and tens of millions invested into tools/methods to support public health led to unique computational chemistry expertise now licensed by Spektron Founded in late 2016, Spektron raised seed funding and established a team of scientists to further develop the FDA technologies into a commercial platform for designing new drugs Spektron is now seeking Series A financing to complete its Q-MAP platform and engineer its first three marketable drug molecules for sale to big pharma companies Spektron s mission is to create exponential value for investors 4
6 Q-MAP vs. Conventional Discovery The Technology Spektron s unparalleled competitive advantage is its Q-MAP technology Begin with smaller, curated set of ~10k molecules Begin with large set of ~100k molecules A unique, disruptive drug discovery method In silico front-end design of molecules Computer prediction of efficacy, toxicology, receptor binding & ADMET Uses molecule Spectral and Quantum Descriptors to outperform methods that use Structure alone Doesn t require costly lab space Massively scalable, including across multiple drug classes In silico screening & design 1 IND to clinical trials Wet-lab, HTS and other in vitro assays ~ 3 yrs ~ 10 yrs > 50% chance of success 1 IND to clinical trials < 10% chance of success
7 Global Spending by Geography The Market Pharmaceutical business is among world s largest with over $1 trillion in annual sales U.S. leads with 40% of global drug spending and huge share of R&D investment Growth has been brisk at 6%+ CAGR, but is slowing rapidly as major patent expirations far outpace new drug introductions Shrinking Big Pharma investment threatens discovery of new drugs for a wide range of pressing needs Global Spending by Disease Area / Source: QuintilesIMS Institute (2015)
8 Design in silico Efficacy, Toxicology, Receptor Binding, ADMET The Competition Competition is robust, with about 10 key players But industry rivalry is modest Spektron occupies uncontested space in AI/ML drug design Shortage of new drug rollouts leaves ample room for multiple competitors Structural Design Spectral and Structural Activity Design Design in silico Receptor Binding 7
9 The Business Model Multiple Paths to Revenue & Profit Sell clinical trial-ready drug molecules (INDs) to Big Pharma Collect upfront payments, progress payments & ongoing royalties Provide toxicity screening services Develop drugs initiated by JV partners in exchange for ownership share Fix broken or withdrawn drugs Q-MAP technology/trade secrets remain in-house and proprietary to Spektron New drug molecules Target Customers $ Upfront & Ongoing Payments 8
10 The Management Team Multi-disciplinary technical, scientific, and business team Led by founder David Wolf, MD, recognized expert in taking innovation to commercial operation; pioneer in ultrasound imaging and tissue engineering; professor of biomedical engineering and aeronautics; physician, astronaut COO Tim Dockins is experienced in programming and software product development with a background in machine learning and intelligence systems CSO Robert Cain is an MBA with background in investment banking, IPOs and pharmaceuticals, and experience in strategy, finance and business development for companies ranging from startups to Fortune 500 Technology team includes experts in computational chemistry, bioinformatics, medicinal chemistry, and scientific chemistry, with backgrounds in pharma and at the FDA 9
11 Anticipated Financing & Liquidity Events The Financials Investment Thesis $10M $14M $13.2M Deploy $40 million to complete tech platform and develop first 3 drugs Financing Drug 1 Sale Drug 2 Sale Drug 3 Sale License each drug to Big Pharma companies to manage FDA clinical trials Liquidity Collect payments as drugs move toward and beyond commercial launch: Pro Forma Financial Projections $37m invested in 3-drugs, 2 nd & 3 rd drugs succeed Up-front payments: est. $30M per drug Milestone payments: est. $200M to $1B+ per drug Ongoing royalties: est. 5% - 20% of sales revenue Aim for USD multi-billion sale or IPO after 2 nd successful licensing agreement 10
12 Contacts: Spektron Systems 400 W. Capitol Ave., 17 th fl. Little Rock, AR David Wolf Robert Cain
NEXT BIG WAVE IN PHARMACEUTICAL INDUSTRY
SEPTEMBER 15, 2017 NEXT BIG WAVE IN PHARMACEUTICAL INDUSTRY Team Mavericks Smriti Mittal Pamela Mandal Harendra Prasad IIM Bangalore IIM Bangalore IIM Bangalore Smriti.mittal16@iimb.ernet.in pamela.mandal16@iimb.ernet.in
More informationSuccessful and Faster Drug Development through Data Mining Dirk Belmans, Ph.D. SAS Belgium
Successful and Faster Drug Development through Data Mining Dirk Belmans, Ph.D. SAS Belgium The Life-Cycle of a Successful Pharmaceutical Product Sales Costs Patent Filing R&D time to launch is decreasing
More informationGlobal Contract Research Organization (CRO) Market: Size, Trends & Forecasts ( ) November 2017
Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts (2017-2021) November 2017 Global Contract Research Organization (CRO) Market : Coverage Executive Summary and Scope Introduction/Market
More informationShivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare
Shivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare The world of healthcare is changing - with two revolutionary technologies, genomics and blockchain poised to significantly
More informationBetter Portfolio Decisions through Predictive Analytics
Better Portfolio Decisions through Predictive Analytics Speakers Jamie Munro, Global Practice Leader, Portfolio & Licensing, Clarivate Analytics Karthik Subramanian, Competitive Intelligence & Clinical
More informationHow to Build a Molecular Testing Laboratory: Key Strategic & Operational Considerations. The complete guide to developing or expanding your lab
How to Build a Molecular Testing Laboratory: Key Strategic & Operational Considerations The complete guide to developing or expanding your lab Includes step-by-step plans for basic and full-service MDx
More informationGUIDE HEA
Companies are often overwhelmed by the field of digital health. From digital and med device companies to biotechnology and pharmaceutical companies, there is a struggle to cut through the noise of numerous
More informationSmarter Healthcare across the Lifecycle with Analytics
Smarter Healthcare across the Lifecycle with Sponsored by IBM Srini Chari, Ph.D., MBA August 2018 mailto:info@cabotpartners.com Executive Summary Healthcare is rapidly evolving from volume-based care to
More informationNew Cardinal Health (Post-Spin)
New Cardinal Health (Post-Spin) George Barrett Vice Chairman and Chief Executive Officer Healthcare Supply Chain Services and Chief Executive Officer Cardinal Health, Inc. (post-spin) January 14, 2009
More informationMedivir Corporate Presentation December, A research-based pharmaceutical company focused on infectious diseases and oncology
Medivir Corporate Presentation December, 2015 A research-based pharmaceutical company focused on infectious diseases and oncology 2 Balanced platform of innovation and revenue generation Locations and
More informationPrecision Medicine & Health Insurance Business Model Disruption? A Data& Evidence perspective
Precision Medicine & Health Insurance Business Model Disruption? A Data& Evidence perspective December 12 th, 2017 Dr. Tim Wintermantel Real World Insights Lead, Switzerland Copyright 2017 IQVIA. All rights
More informationDefining the Expertise for the 21 st Century Neuroscience Workforce. James E. Barrett, Ph.D. Professor and Chair
Defining the Expertise for the 21 st Century Neuroscience Workforce James E. Barrett, Ph.D. Professor and Chair Department of Pharmacology and Physiology Drug Discovery and Development Program at Drexel
More informationMicar Innovation. Drug Discovery Factory for novel drug molecules
Problem There are so many incurable diseases around the world that need adequate novel compounds for the treatment, like: - Chronic pain still a pandemic in the 21 st century and affecting 1.5bn people
More informationTechnology Transfer, Academic and Industry Cooperations
Technology Transfer, Academic and Industry Cooperations Jake Micallef PhD MBA COO ValiRx plc Visiting lecturer Simfonec Jake.micallef@valirx.com What do they want? Universities Money to fund research and
More informationBayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms
Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms Genomics Bioinformatics HTS Combinatorial chemistry Protein drugs
More informationGlobal leader in predictive diagnostics ASX: PIQ
Corporate Review Sydney Canary Capital 6 th June 2017 Global leader in predictive diagnostics ASX: PIQ 1 Business model Three synergistic business areas Unifying Promarker platform technology - leverage
More informationAn AI/ML-Enabled Defense
An AI/ML-Enabled Defense Fully Leveraging Artificial Intelligence/Machine Learning to Make Better Predictions. Faster. Chris Devaney, COO Mission: Teach machines to do data science Better Predictions.
More informationJefferies 2018 Global Healthcare Conference. June 7, 2018
Jefferies 2018 Global Healthcare Conference June 7, 2018 Forward-Looking Statements Statements in this presentation regarding the future financial and operating results, outlook, growth, prospects, business
More informationImaging not only apoptosis. 30 October 2018 AusBiotech Australia Biotech Invest & Partnering 2018 Dr Barbara Meurer Chief Executive Officer
Imaging not only apoptosis. 30 October 2018 AusBiotech Australia Biotech Invest & Partnering 2018 Dr Barbara Meurer Chief Executive Officer 1 The company and a strong IP position Melbourne based biotech
More informationA Potential Innovative CMC Solution: Responding To Public Health Needs With An Accelerated Clinical Pathway A Vaccine Example
A Potential Innovative CMC Solution: Responding To Public Health Needs With An Accelerated Clinical Pathway A Vaccine Example January 2018 Natalie A. Christian Integrated Development and Supply Team Lead
More informationPharmaPerspectiveonCDx. DrGillian Ellison
PharmaPerspectiveonCDx DrGillian Ellison Pharma Perspective Need for CDx Partnering with Dx company Co- development Launch readiness & LCM Need for CDx Drug development Drug development is a challenging
More informationKey Activities. Ofer Reizes, Ph.D. Skills Development Director
Key Activities Ofer Reizes, Ph.D. Skills Development Director 1 Key Activities Core Question: What key activities required for your Value Propositions? Key Partners Key Activities Key Resources Value Proposition
More informationCCTG initiative. patient reported outcomes (including wearables)
Executive Summary Canada can be a global leader in the next generation of pharmaceutical and cancer care innovation. The Canadian Cancer Trials Group (CCTG) is requesting $39 million in federal funding
More information2018 North American Real-World Evidence Enterprise Solutions Market Leadership Award
2018 North American Real-World Evidence Enterprise Solutions Market Leadership Award 2018 2018 NORTH AMERICAN REAL-WORLD EVIDENCE ENTERPRISE SOLUTIONS MARKET LEADERSHIP AWARD Contents Background and Company
More informationKonica Minolta to Acquire Invicro (US)
Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September
More informationThe Right Molecules. Designed. Delivered.
The Right Molecules. Designed. Delivered. 400+ Worldwide Clients 80+ Medicinal Chemistry Programs 20+ Preclinical Candidates Delivered Since 2008 10+ In IND Stage 5 Entered Phase I Clinical Trials 2 Entered
More informationCareer Growth Areas in Physiology / Pharmacology
Career Growth Areas in Physiology / Pharmacology Magdalena Alonso-Galicia, PhD Pharmacology Department Forest Research Institute, Inc. Jersey City, NJ 1 Career Growth Areas in BioPharma n Pharmaceutical
More informationAKESOgen, Inc, 3155 Northwoods Place, NW, Norcross, GA 30071, USA Tel: +1 (770) Page 1
Page 1 HLA Sequencing Based Typing Workflow: A- Sample Collection: iswab-discovery (Mawi DNA Technologies) - Sample was transported by standard US postal services mail, no cold chain of any sort was involved
More informationHealthcare Innovation Trends: What's Happening, Why, and What you Should be Doing About It
Deck @ bit.ly/dvhimss18 Healthcare Innovation Trends: What's Happening, Why, and What you Should be Doing About It Steve Barsh steveb@dreamit.com +1.215.888.2101 @dreamit @sbarsh Venture Accelerator 9+
More informationADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless.
ADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless. COMMUNICATE INNOVATE EXPLORE COLLABORATE PARTNERSHIPS THAT BENEFIT YOU, US, AND ALL OF MANKIND Since Eli Lilly and Company was founded
More informationIntellectual Property and Academic- Industrial Collaboration
Intellectual Property and Academic- Industrial Collaboration J. Denry Sato, D.Phil Visiting Professor of Industry-Academia- Government Collaboration Hiroshima University Funding Problem for Educational
More informationTechnology Development Funding Program Round 3
Technology Development Funding Program Round 3 CWRU January 26, 2015 1 Program Overview NIH Center for Accelerated Innovations (NCAI) at Cleveland Clinic Mission to improve translation of basic science
More informationFrom Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager
From Discovery to Development of new Drugs. and pitfalls along the way by Kim Dekermendjian, PhD in Medicine BD & Key Account manager The roots of Drug Discovery Before 20 th century the term didn't exists,
More informationInvesting in Rare Disease Patient Advocacy Groups
Investing in Rare Disease Patient Advocacy Groups Written by: Pooja Doshi, Engagement Manager, ClearView Healthcare Partners Chris Von Seggern, Partner, ClearView Healthcare Partners Patient Advocacy Groups
More informationForesee Pharmaceuticals, Inc.
Foresee Pharmaceuticals, Inc. Rapid Development and Commercialization of a Proprietary Sustained-release Depot Formulation of Leuprolide for the Treatment of Advanced Prostate Cancer PNWBIO Meeting 10
More informationCompany Report Daring to be different
Company Report 2010 Daring to be different Daring to be different Galapagos has continued to follow its own unique path and is now a leading international biotechnology company. In our 2010 report, we
More informationMaximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date
F o r a c l e a r e r m a r k e t p e r s p e c t i v e Early Stage Drug Safety Strategies & Risk Management Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y Report
More informationIntroduction to Drug Design and Discovery
Introduction to Drug Design and Discovery Course: Drug Design Course code: 0510412 Dr. Balakumar Chandrasekaran Dr. Bilal Al-Jaidi Assistant Professors, Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy,
More informationA Next Generation Stem Cell Therapeutics Company. Investor Presentation: Cynata Therapeutics Limited
A Next Generation Stem Cell Therapeutics Company Investor Presentation: Cynata Therapeutics Limited Important Information This presentation has been prepared by Cynata Therapeutics Limited. ( Cynata or
More informationQ Financial Results and Highlights
Q1 2018 Financial Results and Highlights May 4, 2018 On Today s Earnings Call Stanley Crooke, M.D., Ph.D. Chief Executive Officer and Chairman Beth Hougen Chief Financial Officer Sarah Boyce President
More informationBio-Pharma: China A Look at The FUTURE: 4 th & 5 th Generation Global Strategies
Global Strategy Global Challenges Executable Solutions Bio-Pharma: China 2010-2020 A Look at The FUTURE: 4 th & 5 th Generation Global Strategies France Houdard Managing Director January 2010 Table of
More informationREIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
More informationDelivering Quality Services to All Who Serve. Digital Labor
Delivering Quality Services to All Who Serve Digital Labor Speakers David A. Fitz is KPMG s Lead Partner for the U.S. Department of Veterans Affairs and leads the Federal Corporate Services Network which
More informationGlobal Allied Pharmaceuticals, LLC. Innovation, Research, and Technology. Breaking the bounders, first in its class, thinking outside the box.
Global Allied Pharmaceuticals, LLC. Innovation, Research, and Technology. Breaking the bounders, first in its class, thinking outside the box. The purpose of this presentation Looking for Joint Venture
More informationCrucial Questions for Applying AI in Startups
Crucial Questions for Applying AI in Startups Barney Pell, Ph.D. Founder: Powerset, Moon Express, LocoMobi Associate Founder: Singularity University Fellow: Creative Disruption Lab Advisor: CrowdFlower,
More informationFDA Driving Biomedical Product Innovation
FDA Driving Biomedical Product Innovation Vicki Seyfert-Margolis, Ph.D. Senior Advisor, Science Innovation and Policy Office of the Commissioner November 12, 2012 1 FDA Mission FDA is charged with protecting
More informationto acquire Investor And Analyst Call Presentation January 4, 2008
to acquire Investor And Analyst Call Presentation January 4, 2008 Safe Harbor Statement The following information contains, or may be deemed to contain, forward looking statements (as defined in the U.S.
More informationAssembly Biosciences Jefferies 2015 Microbiome Summit. December 16, 2015
Assembly Biosciences Jefferies 2015 Microbiome Summit December 16, 2015 Forward-Looking Statements This presentation contains forward-looking statements regarding future events. Forward-looking statements
More informationCL King Best Ideas Conference
Leadership in Surface Modification and Drug Delivery Phil Ankeny, Senior Vice President and CFO CL King Best Ideas Conference The Omni Berkshire Place Hotel September 19, 2007 Safe Harbor Statement Some
More informationA full-service CRO with integrated early-stage capabilities
CHARLES RIVER TO ACQUIRE ARGENTA and BIOFOCUS A full-service CRO with integrated early-stage capabilities James C. Foster Chairman, President & CEO Thomas F. Ackerman Executive Vice President & CFO March
More informationPIONEERING WORLD-CLASS DRUG DISCOVERY IN AFRICA
PIONEERING WORLD-CLASS DRUG DISCOVERY IN AFRICA MISSION & VISION Prof. Kelly Chibale H3D Director Vision To be the leading organisation for integrated drug discovery and development on the African continent.
More informationModerna Therapeutics Announces Transition to a Clinical Stage Company, Provides Business Update and Outlines 2016 Strategic Priorities
Moderna Therapeutics Announces Transition to a Clinical Stage Company, Provides Business Update and Outlines 26 Strategic Priorities First Phase I study underway in Europe for mrna 44; IND for second program,
More informationVoyager Therapeutics - A Spinout from UMass Gene Therapy and RNAi Technologies
University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2016 UMass Center for Clinical and Translational Science Research Retreat
More informationUnderstanding How The Indian Pharmaceutical Industry Works Part 3
Understanding How The Indian Pharmaceutical Industry Works Part 3 Key Performance Indicators Pharmaceutical Sector Sales & Marketing Marketing always starts with the customer and ends with the customer
More informationOn behalf of the Cystic Fibrosis Foundation (CFF) and the 30,000 people with cystic
Robert J. Beall, Ph.D. President and Chief Executive Officer Cystic Fibrosis Foundation On behalf of the Cystic Fibrosis Foundation (CFF) and the 30,000 people with cystic fibrosis (CF) in the United States,
More informationOctober Nasdaq (CGIX) A Leader in Precision Oncology. Nasdaq (CGIX)
October 2018 Nasdaq (CGIX) A Leader in Precision Oncology Nasdaq (CGIX) Disclaimer These slides may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationStart With the End in Mind A Diagnostic Company s Perspective on Companion Diagnostic Development. Paul Docherty PhD Relationship Management
Start With the End in Mind A Diagnostic Company s Perspective on Companion Diagnostic Development Paul Docherty PhD Relationship Management Disclaimer This presentation contains my personal views and research
More informationIntelligent Process Automation. The key to automating, orchestrating, and optimizing the modern workplace
Intelligent Process Automation The key to automating, orchestrating, and optimizing the modern workplace It s time to break the backlog Nintex Intelligent Process Automation 2 Disrupt or be disrupted The
More informationJefferies Global Health Care Conference. June 1, 2015
Jefferies Global Health Care Conference June 1, 2015 Forward-Looking Statements This presentation may contain projections, estimates and other forwardlooking statements that involve a number of risks and
More informationInnovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing
Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from
More informationIntellectual property: The driving force for growth and funding
Judith E. Schneider is Chairman and Chief Executive Officer of The BPI Group Limited, a leading professional services firm providing strategic advisory and business plan development services to emerging
More informationJefferies Healthcare Conference June 8, Protein Engineering. Transform Your Thinking
Jefferies Healthcare Conference June 8, 2017 Protein Engineering Transform Your Thinking Forward-Looking Statements These slides contain forward-looking statements that involve risks and uncertainties.
More informationFast Track Drug Development The Clinical (Caleidoscopic) Perspective
20 Years AGAH, Annual Meeting, Hamburg 21.-23. February 2010 Fast Track Drug Development The Clinical (Caleidoscopic) Perspective Fritz R. Bühler, MD ECPM, University of Basel European Innovative Medicine
More informationKRISANI BIO SCIENCES PVT. LTD.
KRISANI BIO SCIENCES PVT. LTD. Flat B2, 2 nd Floor, Suryateja Apartments, Hindi Nagar, Punjagutta, Hyderabad, Telangana 500078. Email: kkr@krisanibio.com. URL: www.krisanibio.com Contact Number: +91 98494
More informationUNLEASH THE POWER OF PRECISION MEDICINE
FROM BENCH TO BEDSIDE UNLEASH THE POWER OF PRECISION MEDICINE DCB, pioneer in biotech. Your partner in drug discovery. www.dcb.org.tw The Center for Biotechnology With over 400 dedicated researchers and
More informationNanotechnology: A new way to fight cancer?
HKU Ecom-Icomp Expert Address Series 2015 Nanotechnology: A new way to fight cancer? Professor Amy Shuen and CEO, Nanoforma November 11, 2015 Nanoforma contact: amy@nanoforma.com 1 A Fantastic Voyage http://www.tubechop.com/watch/7174947
More informationWRITING A SUCCESSFUL SBIR / STTR COMMERCIALIZATION PLAN. Ed Kase Business Development Consultant
WRITING A SUCCESSFUL SBIR / STTR COMMERCIALIZATION PLAN Ed Kase Business Development Consultant About Ed Kase BS in mechanical engineering from Clarkson University MBA from Colorado State University 20+
More informationOpen Innovation March 2014
Open Innovation March 2014 Open innovation Necessity is the mother of all invention English Proverb ascribed to Plato. Is Open Innovation an idea born out of necessity to survive for big Pharma? Open innovation
More informationQuick Start with AI for Businesses
Quick Start with AI for Businesses ML Conference 2018, Dr. Ulrich Bodenhausen, AI Coach V1.0 2018-06-12 About me PhD in Machine Learning from KIT. Application of neural networks to speech and gesture recognition
More informationFor personal use only
Shareholder Presentation Perth, WA Annual General Meeting 17th November 2016 Global leader in applying proteomics to MedTech ASX: PIQ 1 Disclaimer & forward-looking statements This Presentation is provided
More informationCEOCFO Magazine. Dr. Jakub Staszak-Jirkovsky Co-Founder and Chief Executive Officer. Machavert Pharmaceuticals
CEOCFO Magazine ceocfointerviews.com All rights reserved Issue: February 11, 2019 Developing the first Drug Candidates based on Phospholipid that Activates Natural Killer Cells, Machavert Pharmaceuticals
More informationTHE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS
THE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS What all developers need to know Alicia Baker Director, Global Regulatory Affairs Strategy, Covance John Carlsen, MHA Vice President,
More informationProMetic Life Sciences Inc. Biotech Showcase San Francisco January, 2011
ProMetic Life Sciences Inc. Biotech Showcase San Francisco January, 2011 1 Forward Looking Statement / Copyright notice / Disclaimer Forward Looking Statement This presentation contains forward-looking
More informationBREAKTHROUGH INNOVATION: LESSONS FOR PHARMA R&D
BREAKTHROUGH INNOVATION: LESSONS FOR PHARMA R&D Novasecta: Specialist Pharmaceutical Management Consulting The realities of unrelenting price pressure and patent expiries put a special pressure on pharmaceutical
More informationSELECTED EXCERPTS FROM Intellectual Property Provisions in Clinical Trial Agreements
SELECTED EXCERPTS FROM Intellectual Property Provisions in Clinical Trial Agreements MAGI East Clinical Research Conference 2014 Philadelphia, PA May 4-7, 2014 Sharon Tasman Prysant, Principal Health &
More informationAbout Sarepta Therapeutics
Sarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Brammer Bio to Support Gene Therapy Development and Commercial Supply -- The partnership will provide commercial supply
More informationPaving the way to FDA? tips and pitfalls. The Nextar start up support program Dr. Orna Dreazen- CEO
Paving the way to FDA? tips and pitfalls The Nextar start up support program Dr. Orna Dreazen- CEO ornad@nextar.co.il Drug Development Process Discovery Development Commercial Market Basic Research Pre-Clinical
More informationChallenges of Biomarker Development. (in Europe)
Challenges of Biomarker Development (in Europe) 1 Disclaimer I work for industry (diagnostics) We have worked with over 30 biopharma companies in the arena of biomarkers The presentation is my own and
More informationUtilizing CipherShare within Pharmaceutical and Biotechnology Industries
Utilizing CipherShare within Pharmaceutical and Biotechnology Industries Table of Contents Table of Contents... 2 1. Securing High-Value Intellectual Property... 3 2. Regulatory Pressure to Secure Privacy
More informationVertex and Moderna Establish Exclusive Collaboration to Discover and Develop mrna Therapeutics for Cystic Fibrosis
Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mrna Therapeutics for Cystic Fibrosis -Collaboration to explore use of mrna Therapeutics to treat the underlying cause of CF
More informationIndustry Pharmaceutical
Industry White Paper IT trends in Indian Abstract The Indian pharmaceutical industry is today the fourth largest globally in volume terms and 13 th largest in value terms and continues to grow annually
More informationPharma Company fills Regulatory, Compliance and Pharmacovigilance positions in remote locations. A Compunnel Case Study on Pharmaceutical Staffing
Pharma Company fills Regulatory, Compliance and Pharmacovigilance positions in remote locations A Case Study on Pharmaceutical O VERVIEW Difficult to fill positions in a highly remotest areas High Time-to-fill
More informationImpact of Artificial Intelligence on Recruiting
Impact of Artificial Intelligence on Recruiting Faster, Cheaper, and more Predicable How AI is solving the biggest recruiting inefficiencies The most important general-purpose technology of our era is
More informationInaugural Fraunhofer Delaware Technology Summit
Inaugural Fraunhofer Delaware Technology Summit Energy and Life Sciences Solu
More informationDefinitive Merger Agreement Conference Call
Definitive Merger Agreement Conference Call Committed to providing products and services that ensure the best possible patient outcomes August 15, 2017 NASDAQ: SKLN Forward-Looking Statements This presentation
More informationJefferies TMT Conference
Jefferies TMT Conference Tarek Sherif, Chairman and CEO Cory Douglas, CFO May 9, 2013 2013 Medidata Solutions, Inc. 1 Safe Harbor Statement This presentation contains forward-looking statements within
More informationCASE STUDY: INVESTMENT MANAGEMENT FIRM TRANSFORMS PORTFOLIO MANAGEMENT TO MAKE TRADING DECISIONS IN REAL TIME
CASE STUDY: INVESTMENT MANAGEMENT FIRM TRANSFORMS PORTFOLIO MANAGEMENT TO MAKE TRADING DECISIONS IN REAL TIME INTRODUCTION A leading investment management firm dedicated to evidence-based investing in
More informationErika Smith - Director of the Blavatnik Fund for Innovation at Yale
Erika Smith - Director of the Blavatnik Fund for Innovation at Yale erika.smith@yale.edu 1 GOAL: Advance Yale s biomedical technologies to the stage where they are ready for partnership (i.e. bridge the
More informationWHILE A SMALL NUMBER OF PEOPLE ARE SUFFERING FROM A SINGLE RARE DISEASE, 350 MILLION PEOPLE WORLDWIDE ARE SUFFERING FROM RARE DISEASES.
June 2017 WHILE A SMALL NUMBER OF PEOPLE ARE SUFFERING FROM A SINGLE RARE DISEASE, 350 MILLION PEOPLE WORLDWIDE ARE SUFFERING FROM RARE DISEASES. 3rd most populous country 50% of affected are children
More informationSanten Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device
Santen Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device Akira Kurokawa President & CEO August 2, 2016 Copyright 2016 Santen Pharmaceutical Co., Ltd. All rights reserved. 1 External
More informationIncrease Value and Reduce Total Cost of Ownership and Complexity with Oracle PaaS
Increase Value and Reduce Total Cost of Ownership and Complexity with Oracle PaaS Oracle PaaS Reduces Operating Costs and Drives Value Creation O R A C L E W H I T E P A P E R 2 0 1 7 Executive Summary
More informationCogstate Ltd. (CGS) Summary (AUD) Key Financials (A$ million) Share Price Graph (AUD)
Cogstate Ltd. (CGS) 7 August, 2017 Outperform 4Q17: Slow Growth, but CGS is Well-Positioned Price Target: $1.27 Elyse Shapiro eshapiro@taylorcollison.com.au +61 4 9126 7142 Summary (AUD) Market Capitalisation
More informationGROWTH OF CONNECTED MEDICAL DEVICES & PHARMA MEDICAL TECHNOLOGY
GROWTH OF CONNECTED MEDICAL DEVICES & PHARMA MEDICAL TECHNOLOGY GROWTH OF CONNECTED MEDICAL DEVICES & PHARMA ARTICLE The digital health revolution has been fuelled primarily by growing use of wearable
More informationJanuary 2018 ASX: RCE. Recce Pharmaceuticals Ltd
January 2018 ASX: RCE Recce Pharmaceuticals Ltd Tackling Superbugs RECCE 327 1 Corporate summary Commercialising promising new class of synthetic antibiotics Focus is new treatments for drug resistant
More informationMODEL-BASED DRUG DEVELOPMENT: A FDA CRITICAL PATH OPPORTUNITY
MODEL-BASED DRUG DEVELOPMENT: A FDA CRITICAL PATH OPPORTUNITY Donald R. Stanski MD Scientific Advisor, Office of the Commissioner, FDA Professor of Anesthesia Stanford University, CA THE OPINIONS EXPRESSED
More informationStrategy of Successful Alliance for Domestic Biopharma
Strategy of Successful Alliance for Domestic Biopharma November 14, 2005 Sukwoo (Jeffrey) Oh, J.D. President & CEO SMART Biosciences, Inc. & Managing Director Roberts Mitani, LLC 1 Common Biopharma Myths
More informationInvestor Overview Presentation ADVANCING LIFE SCIENCE TOGETHER
Investor Overview Presentation ADVANCING LIFE SCIENCE TOGETHER Forward-Looking Statement Disclaimer In order to take advantage of the safe harbor provisions of the private securities litigation reform
More informationUniversity of Connecticut Student Managed Fund 2018 Analyst Report. Jonathan Stryjek & Michael Pehota
University of Connecticut Student Managed Fund 2018 Analyst Report Jonathan Stryjek & Michael Pehota Table of Contents 3 Report Highlights 4 Business Overview 5 Industry Overview and Competitive Positioning
More informationMarketing Your Business to Investors
Marketing Your Business to Investors Can You Manage Money? Steven Rogers, Redstones LLC srogers@redstones.com www.redstones.com 1 Always Remember This is my perspective of finding money based on my experience
More informationBY PEOPLE. WITH PEOPLE. FOR PEOPLE.
BY PEOPLE. WITH PEOPLE. FOR PEOPLE. :: 4SC AG, ENNO SPILLNER KORRELATION UNTERNEHMENSNACHRICHTEN & UNTERNEHMENSBEWERTUNG BERLIN, 19. MÄRZ 2013 FORWARD LOOKING STATEMENTS This presentation may contain projections
More information